• news.cision.com/
  • STENOCARE/
  • STENOCARE A/S: The subscription period in Stenocare’s conditional rights issue begins today for the time limited offer of DKK 0,50 per new share
English

STENOCARE A/S: The subscription period in Stenocare’s conditional rights issue begins today for the time limited offer of DKK 0,50 per new share

Report this content

STENOCARE A/S
NASDAQ FIRST NORTH GROWTH MARKET, DENMARK
TICKER:  STENO

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE.

Today, January 7, 2025, the subscription period in STENOCARE A/S’ ("Stenocare" or the "Company") rights issue begins. The last day of the subscription period is January 20, 2025. A total of 40,424,994 new shares are issued at a subscription price of 0.50 DKK per new share. The Rights Issue is conditional upon 18,191,248 new shares being subscribed for, corresponding to approximately 45 percent of the total issue, raising approximately 9.1 mDKK before deduction of transaction costs. The Company has secured 1.5 mDKK through binding pre-commitments and compensation free guarantees from management and shareholders.

Summary of the Rights Issue:

The Rights Issue is to be carried out on the following main terms:

  • The Rights Issue is with pre-emptive rights for existing shareholders exercising the granted authorization clause 5.9 at the Extraordinary General Meeting held on 18 December 2024.
  • Existing shareholders received two (2) subscription rights for every one (1) existing share, which were held on the record date of 6 January 2025. One (1) subscription right entitles the holder to subscribe for one (1) new share in the Company.
  • The Rights Issue comprises a maximum of 40,424,994 new shares.
  • The subscription price is set at 0.50 DKK per new share during January 07 – 20, 2025
  • The last day of trading in the Stenocare share, including the right to receive subscription rights in the Rights Issue was 2 January 2025.
  • The subscription period runs from today, 7 January 2025, 9.00 A.M. CET and ends on 20 January 2025, 5.00 P.M. CET.
  • Upon full subscription of the Rights Issue, Stenocare will be provided with approximately 20.2 mDKK before deduction of transaction-related costs.

Important dates

  • 7 January 2025: First day of subscription period
  • 16 January 2025: Last day of trading period of subscription rights
  • 20 January 2025: Last day of subscription period
  • 22 January 2025: Announcement of result of Rights Issue
  • 24 January 2025: Expected registration of the capital increase at Danish Business Authority
  • 28 January 2025: First day of trading new shares

More information

For more information about Stenocare and the Rights Issue, please use the following link: https://stenocare.com/share-issue-2025/, or the press release published on 18 December 2024.

Important notice

This announcement is for the information of the Company's shareholders and does not constitute an offer or invitation to subscribe for or purchase subscription rights or shares in the Company. There is no public offer of shares outside Denmark. Persons outside Denmark who come into possession of information about the Rights Issue are advised by the Company to observe any restrictions and should inform themselves about the legislation, including tax consequences, that may be relevant to them prior to investing in shares issued by STENOCARE A/S.

This announcement contains certain forward-looking statements, including statements about the Company's operations. Such forward-looking statements are based on information, assumptions and estimates that the Company believes are reasonable. These forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause the Company's actual results, performance or achievements or industry performance to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. If one or more of these risks or uncertainties materialize, or if an underlying assumption proves incorrect, the Company's actual financial position or results of operations could differ materially from those described as assumed, evaluated, estimated or expected.

For additional information regarding STENOCARE, please contact:
Thomas Skovlund Schnegelsberg, CEO          Phone: +45 31770060            E-mail: presse@stenocare.com

About STENOCARE A/S
STENOCARE A/S, founded in 2017, supplies prescription-based medical cannabis to patients in Denmark and internationally. It was the first company to receive permission from the Danish Medicines Agency to import, distribute, cultivate, and produce medical cannabis. Today, STENOCARE sources its products from a selection of high-quality international suppliers that comply with the strict European Good Manufacturing Practices (EU-GMP). STENOCARE has developed a unique patented medical cannabis oil product, ASTRUM, which provides improved bioavailability of active ingredients for patients. The company has strategically invested in assets to operate within the highly regulated pharmaceutical industry, with products approved for sale in multiple countries.
www.stenocare.com    www.stenocare.dk   www.stenocare.se

Subscribe

Documents & Links